Stuart Poulton
Corporate Officer/Principal bij KARYOPHARM THERAPEUTICS INC.
Vermogen: 38 926 $ op 30-04-2024
Profiel
Stuart Poulton is currently the Chief Development Officer & Executive VP at Karyopharm Therapeutics, Inc. Prior to his current position, he worked as the Executive Director-Global Program Management at Amgen, Inc. from 2013 to 2016.
He also held the position of Head-Clinical Operations at Eli Lilly & Co. Additionally, Mr. Poulton served as the Vice President-Clinical Development Operations at AbbVie, Inc. from 2019 to 2022.
He completed his graduate degree at The University of New South Wales and his undergraduate degree at The University of Sydney.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 29-03-2024 | 36 723 ( 0.03% ) | 38 926 $ | 30-04-2024 |
Actieve functies van Stuart Poulton
| Bedrijven | Functie | Begin |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Corporate Officer/Principal | 01-02-2022 |
Eerdere bekende functies van Stuart Poulton
| Bedrijven | Functie | Einde |
|---|---|---|
| ABBVIE INC. | Corporate Officer/Principal | 01-01-2022 |
| AMGEN INC. | Corporate Officer/Principal | 01-01-2016 |
| ELI LILLY AND COMPANY | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Stuart Poulton
| The University of Sydney | Undergraduate Degree |
| The University of New South Wales | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| ABBVIE INC. | Health Technology |
| AMGEN INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
